Integrative data analysis of clinical trials network studies to examine the impact of psychosocial treatments for black people who use cocaine: Study protocol.
Black/African American
Comparative effectiveness
Integrated data analysis
NIDA clinical trials network
Stimulants
Substance use treatment
Journal
Contemporary clinical trials
ISSN: 1559-2030
Titre abrégé: Contemp Clin Trials
Pays: United States
ID NLM: 101242342
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
24
03
2023
revised:
22
08
2023
accepted:
28
08
2023
medline:
13
11
2023
pubmed:
1
9
2023
entrez:
31
8
2023
Statut:
ppublish
Résumé
Cocaine overdose death rates among Black people are higher than that of any other racial/ethnic group, attributable to synthetic opioids in the cocaine supply. Understanding the most effective psychostimulant use treatment interventions for Black people is a high priority. While some interventions have proven effective for the general population, their comparative effectiveness among Black people remains unknown. To address this gap, our NIDA-funded Clinical Trials Network (CTN) study (0125), will use Integrative Data Analysis (IDA) to examine treatment effectiveness across 9 CTN studies. This manuscript describes the study protocol for CTN-0125. Of the 59 completed randomized clinical trials in the CTN with available datasets, nine met our inclusion criteria: 1) behavioral intervention, 2) targeted cocaine use or use disorder, 3) included sub-samples of participants who self-identified as Black and 4) included outcome measures of cocaine and psychostimulant use and consequences. We aim to 1) estimate scale scores of cocaine use severity while considering study-level measurement non-invariance, 2) compare the effectiveness of psychosocial treatments for psychostimulant use, and 3) explore individual (e.g., concomitant opioid use, age, sex, employment, pre-treatment psychiatric status) and study-level moderators (e.g., attendance/retention) to evaluate subgroup differences in treatment effectiveness. The NIDA CTN provides a unique collection of studies that can offer insight into what interventions are most efficacious for Black people. Findings from our CTN-0125 study have the potential to substantially inform treatment approaches specifically designed for Black people who use psychostimulants.
Sections du résumé
BACKGROUND
BACKGROUND
Cocaine overdose death rates among Black people are higher than that of any other racial/ethnic group, attributable to synthetic opioids in the cocaine supply. Understanding the most effective psychostimulant use treatment interventions for Black people is a high priority. While some interventions have proven effective for the general population, their comparative effectiveness among Black people remains unknown. To address this gap, our NIDA-funded Clinical Trials Network (CTN) study (0125), will use Integrative Data Analysis (IDA) to examine treatment effectiveness across 9 CTN studies. This manuscript describes the study protocol for CTN-0125.
METHODS
METHODS
Of the 59 completed randomized clinical trials in the CTN with available datasets, nine met our inclusion criteria: 1) behavioral intervention, 2) targeted cocaine use or use disorder, 3) included sub-samples of participants who self-identified as Black and 4) included outcome measures of cocaine and psychostimulant use and consequences. We aim to 1) estimate scale scores of cocaine use severity while considering study-level measurement non-invariance, 2) compare the effectiveness of psychosocial treatments for psychostimulant use, and 3) explore individual (e.g., concomitant opioid use, age, sex, employment, pre-treatment psychiatric status) and study-level moderators (e.g., attendance/retention) to evaluate subgroup differences in treatment effectiveness.
CONCLUSION
CONCLUSIONS
The NIDA CTN provides a unique collection of studies that can offer insight into what interventions are most efficacious for Black people. Findings from our CTN-0125 study have the potential to substantially inform treatment approaches specifically designed for Black people who use psychostimulants.
Identifiants
pubmed: 37652354
pii: S1551-7144(23)00252-5
doi: 10.1016/j.cct.2023.107329
pmc: PMC10635737
mid: NIHMS1936590
pii:
doi:
Substances chimiques
Cocaine
I5Y540LHVR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107329Subventions
Organisme : NIAAA NIH HHS
ID : K23 AA028515
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1 DA015815
Pays : United States
Organisme : NIDA NIH HHS
ID : R25 DA035163
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA060441
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA028778
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA025853
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1 DA013732
Pays : United States
Organisme : NIDA NIH HHS
ID : L30 DA049246
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1 DA015831
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA057651
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Matern Child Health J. 2022 Oct;26(10):2090-2108
pubmed: 35947278
Am J Addict. 2014 May-Jun;23(3):294-9
pubmed: 24724888
Psychol Methods. 2010 Sep;15(3):234-49
pubmed: 20822250
Contemp Clin Trials. 2021 Aug;107:106479
pubmed: 34157418
J Consult Clin Psychol. 2009 Aug;77(4):607-19
pubmed: 19634955
Psychiatr Serv. 2004 Feb;55(2):167-73
pubmed: 14762242
J Subst Abuse Treat. 2009 Jan;36(1):25-43
pubmed: 18550320
Psychol Assess. 2007 Mar;19(1):119-32
pubmed: 17371127
Prev Sci. 2007 Sep;8(3):206-13
pubmed: 17549635
Dev Psychol. 2008 Mar;44(2):365-80
pubmed: 18331129
J Psychoactive Drugs. 2021 Nov-Dec;53(5):394-403
pubmed: 34727839
Stat Med. 2009 Apr 30;28(9):1402-14
pubmed: 19222021
Am J Psychiatry. 2008 Feb;165(2):179-87
pubmed: 18198270
Addict Behav. 2023 Mar;138:107567
pubmed: 36521424
Psychol Addict Behav. 2020 Feb;34(1):117-127
pubmed: 31246072
Lancet Psychiatry. 2022 Aug;9(8):660-675
pubmed: 35752192
J Subst Abuse Treat. 2016 Apr;63:25-33
pubmed: 26818489
J Affect Disord. 2020 Sep 1;274:832-840
pubmed: 32664022
Psychol Methods. 2017 Sep;22(3):507-526
pubmed: 27266798
Psychol Assess. 2020 Nov;32(11):1015-1027
pubmed: 32853005
J Trauma Stress. 2021 Apr;34(2):454-466
pubmed: 33175470
J Trauma Stress. 2022 Jun;35(3):926-940
pubmed: 35124864
Am J Orthopsychiatry. 2019;89(3):354-368
pubmed: 31070421
MMWR Morb Mortal Wkly Rep. 2019 May 03;68(17):388-395
pubmed: 31048676
Addict Sci Clin Pract. 2021 Aug 5;16(1):50
pubmed: 34353373
Contemp Clin Trials. 2022 Apr;115:106705
pubmed: 35176503
Prev Sci. 2018 Feb;19(Suppl 1):60-73
pubmed: 28434055
Psychol Methods. 2009 Jun;14(2):101-25
pubmed: 19485624
Psychol Methods. 2009 Jun;14(2):165-76
pubmed: 19485627
Stat Med. 2016 Jul 10;35(15):2485-502
pubmed: 26841367
Prev Sci. 2022 Sep 3;:
pubmed: 36057023
Prev Sci. 2022 Nov 28;:
pubmed: 36441362
Subst Abus. 2021;42(1):5-12
pubmed: 33465013
Am J Community Psychol. 2016 Dec;58(3-4):422-433
pubmed: 27879003
Lancet. 1993 Feb 13;341(8842):418-22
pubmed: 8094183
Psychol Addict Behav. 2015 Mar;29(1):34-48
pubmed: 25546144
Prev Sci. 2023 Feb 8;:
pubmed: 36753042
Psychol Assess. 2020 Apr;32(4):321-335
pubmed: 31804102
J Ethn Subst Abuse. 2017 Jul-Sep;16(3):380-399
pubmed: 27294812
Int J Methods Psychiatr Res. 2022 Jun;31(2):e1906
pubmed: 35132724
Health Aff (Millwood). 2013 Jan;32(1):135-45
pubmed: 23297281
Am J Epidemiol. 2022 Mar 24;191(4):599-612
pubmed: 35142341
Am J Psychiatry. 2023 Feb 1;180(2):155-166
pubmed: 36475373
Harv Rev Psychiatry. 2021 Mar-Apr 01;29(2):108-130
pubmed: 33666395